40
Participants
Start Date
June 25, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
August 31, 2026
Lomecel-B medicinal signaling cells
A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
Children's Hospital of Philadelphia, Philadelphia
Children's Healthcare of Atlanta, Atlanta
Cincinnati Children's Hospital Medical Center, Cincinnati
Advocate Children's Hospital, Chicago
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Children's Nebraska, Omaha
Children's Hospital Colorado, Aurora
Primary Children's Hospital/University of Utah, Salt Lake City
Children's Hospital of Los Angeles, Los Angeles
Boston Children's Hospital, Boston
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
The University of Texas Health Science Center, Houston
OTHER
Longeveron Inc.
INDUSTRY